Screener
Kyverna Therapeutics, Inc. KYTX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $30,073 | $37,433 |
| General and administrative | 11,294 | 9,975 |
| Total operating expenses | 41,367 | 47,408 |
| Loss from operations | (41,367) | (47,408) |
| Interest income | 2,327 | 2,825 |
| Interest expense | (667) | (25) |
| Other expense, net | (21) | (27) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s other operating expenses?
- Kyverna Therapeutics, Inc. (KYTX) reported other operating expenses of $41.37M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s other operating expenses changed year-over-year?
- Kyverna Therapeutics, Inc.'s other operating expenses decreased by 12.7% year-over-year, from $47.41M to $41.37M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s other operating expenses?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s other operating expenses has grown at a 65.0% compound annual growth rate (CAGR), from $62.41M to $169.83M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Kyverna Therapeutics, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude